8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): February 1, 2002


                        Commission File Number: 000-32021

                                  Centrex, Inc.
                 (Name of Small Business Issuer in its charter)

          Oklahoma                                          73-1554121
          --------                                          ----------
(State or other jurisdiction of                       (IRS Employer I.D. No.)
 incorporation or organization)

                        8908 South Yale Avenue, Suite 409
                           Tulsa, Oklahoma 74137-3545
              (Address of principal executive offices and Zip Code)

                                 (918) 481-0167
              (Registrant's telephone number, including area code)



                                  With copy to:
                             Ronald C. Kaufman, Esq.
                              Kaufman & Associates
                            610 South Main, Suite 210
                                 Tulsa, OK 74119
                                  918-584-4463







Item 5.  Other Events.

On February 1, 2002, the Company announced in a press release the appointment of
Dr. Thomas Coughlin as the Company's CEO and Director and the resignation of Mr.
Gifford Mabie as the Company's officer and director. There were no disagreements
between Mr. Mabie and the Company on any matter.  A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 7.  Financial Statements and Exhibits

         Exhibit No.       Description
         99.1              Press release dated February 1, 2002


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                 CENTREX, INC.

                                 /s/ Thomas R. Coughlin, Jr.
                                 -------------------------------------
                                 By:  Dr. Thomas R. Coughlin, Jr.
                                      Chief Executive Officer


DATED:  February 4, 2002

EX-99

                                  Exhibit 99.1
                      Press Release dated February 1, 2002




                    DR. THOMAS R. COUGHLIN, JR. NAMED OFFICER
                           & DIRECTOR OF CENTREX, INC.


TULSA.  February 1, 2002. Centrex,  Inc. (OTC BB: CNEX) today announced that Dr.
Thomas R. Coughlin,  Jr., the Company's medical advisor,  has been named CEO and
director.  Prior to joining  the Company in January  1999,  Dr.  Coughlin  was a
cardiovascular  and  transplant  surgeon  for more  than 25  years.  He holds an
undergraduate  degree in Chemistry  from Seton Hall  University  (B.S.) and is a
graduate of the University of Rochester School of Medicine and Dentistry (M.D.).
He did his cardiovascular and transplant  surgical training at the University of
Illinois and Cook County Hospital in Chicago.

Dr.  Coughlin was Assistant  Professor  and Chief of  Transplant  Surgery at the
University of Maryland from 1986 to 1990,  starting the heart transplant program
and performing the first successful heart transplant at the University Hospital.
During that time,  he also  served as Medical  Director  of the  Maryland  Organ
Procurement Center. From 1992 to 1995, he was Medical Director of Cardiovascular
Surgical  Services at Alexandria  Hospital in  Alexandria,  VA, and from 1991 to
1995, he was Assistant Clinical Professor,  Thoracic and Cardiovascular Surgery,
at George Washington University Medical Center in Washington, D.C.

From 1995 to January 1999,  Dr.  Coughlin  practiced  cardiovascular  surgery in
Tulsa,  OK and was Assistant  Clinical  Professor at the  University of Oklahoma
Medical School from 1995 to the present.

The former officer and director of the Company, Gifford Mabie, has resigned. Mr.
Mabie has agreed to be a consultant on an as needed basis for the transition.

Centrex owns the exclusive U.S.  license to develop,  manufacture,  and market a
system for  detecting  microbial  contamination  due to E. coli bacteria in air,
food, and water. The detection system, currently in development,  is designed to
be  adaptable  and easily  tailored  to detect a variety of  bacterial  or viral
organisms in real time.  The  organisms  being  considered  for detection by the
device include all those named in the  biological  warfare threat list published
by the Defense  Intelligence  Agency,  in addition  to several  other  potential
biowarfare agents. The proposed device is a simultaneous multi-channel detection
system that is compact,  fully  automated and capable of monitoring the presence
of biological agents in air, food, and water.

Centrex, Inc., an Oklahoma Corporation, is a development stage company organized
in 1998 to identify and commercialize  proprietary  systems for the detection of
biological contaminants in food, air and water.

For more information, visit the Centrex website at www.centrexcorporation.com or
call Investor Relations at 888-492-1257.

This press release  contains some  forward-looking  statements.  We undertake no
obligation to publicly update any forward-looking statement, whether as a result
of new information,  future events or otherwise.  Forward-looking  statements in
this  document  should be evaluated  together with the many  uncertainties  that
affect our  business.  Those  uncertainties  are  discussed in the Company's SEC
filings.

                                      # # #